The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J05 | Antivirals for systemic use | |
| 3 | J05A | Direct acting antivirals | |
| 4 | J05AR | Antivirals for treatment of HIV infections, combinations | |
| 5 | J05AR06 | Emtricitabine, tenofovir disoproxil and efavirenz |
| Active Ingredient | Description | |
|---|---|---|
| Emtricitabine, Tenofovir disoproxil and Efavirenz |
Efavirenz is an NNRTI of HIV-1. Efavirenz non-competitively inhibits HIV-1 reverse transcriptase (RT) and does not significantly inhibit human immunodeficiency virus-2 (HIV-2) RT or cellular deoxyribonucleic acid (DNA) polymerases (α, β, γ, and δ). Emtricitabine is a nucleoside analogue of cytidine. Tenofovir disoproxil is converted in vivo to tenofovir, a nucleoside monophosphate (nucleotide) analogue of adenosine monophosphate. Emtricitabine and tenofovir are phosphorylated by cellular enzymes to form emtricitabine triphosphate and tenofovir diphosphate, respectively, which competitively inhibit HIV-1 reverse transcriptase, resulting in DNA chain termination. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ATENEF Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| ATRIPLA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RIZENE Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
